Cargando…

MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma

PURPOSE: To investigate the significance of MR features based on the Liver Imaging Reporting and Data System (LI-RADS ver. 2018) for identifying the expression of cytokeratin 19 (CK-19) in patients with combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) before surgery. PATIENTS AND METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Changwu, Ni, Xiaoyan, Lu, Xin, Wang, Yi, Qian, Xianling, Yang, Chun, Zeng, Mengsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387586/
https://www.ncbi.nlm.nih.gov/pubmed/34458204
http://dx.doi.org/10.2147/JHC.S325686
_version_ 1783742472892973056
author Zhou, Changwu
Ni, Xiaoyan
Lu, Xin
Wang, Yi
Qian, Xianling
Yang, Chun
Zeng, Mengsu
author_facet Zhou, Changwu
Ni, Xiaoyan
Lu, Xin
Wang, Yi
Qian, Xianling
Yang, Chun
Zeng, Mengsu
author_sort Zhou, Changwu
collection PubMed
description PURPOSE: To investigate the significance of MR features based on the Liver Imaging Reporting and Data System (LI-RADS ver. 2018) for identifying the expression of cytokeratin 19 (CK-19) in patients with combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) before surgery. PATIENTS AND METHODS: The study enrolled 174 patients pathologically confirmed to have cHCC-CCA according to the 2019 WHO classification. The preoperative MR imaging features and clinicopathological findings were retrospectively evaluated and compared between the CK-19-positive and CK-19-negative cHCC-CCA groups. RESULTS: One hundred seventy-four patients (mean age, males vs females: 56.6 ± 10.0 years vs 54.7 ± 14.2 years) were evaluated. The presence of mosaic architecture, targetoid appearance, cholangiectasis, hepatic capsule retraction, and corona enhancement was significantly higher in the CK-19-positive group (all p < 0.05), while nonrim arterial phase hyperenhancement (APHE) was more common in the CK-19-negative group (p = 0.04). The univariate analysis showed that hepatitis B virus infection, CEA > 5 ng/mL, tumor size, nonrim APHE, mosaic architecture, targetoid appearance, cholangiectasis, hepatic capsule retraction, and corona enhancement were significant risk factors for CK-19-positive cHCC-CCA (all p < 0.05). Unfortunately, the multivariate analysis revealed that only corona enhancement (OR = 2.359, p = 0.03) was an independent risk factor associated with CK-19-positive cHCC-CCA. CONCLUSION: Corona enhancement is significantly correlated with CK-19 positivity in patients with cHCC-CCA.
format Online
Article
Text
id pubmed-8387586
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-83875862021-08-26 MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma Zhou, Changwu Ni, Xiaoyan Lu, Xin Wang, Yi Qian, Xianling Yang, Chun Zeng, Mengsu J Hepatocell Carcinoma Original Research PURPOSE: To investigate the significance of MR features based on the Liver Imaging Reporting and Data System (LI-RADS ver. 2018) for identifying the expression of cytokeratin 19 (CK-19) in patients with combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) before surgery. PATIENTS AND METHODS: The study enrolled 174 patients pathologically confirmed to have cHCC-CCA according to the 2019 WHO classification. The preoperative MR imaging features and clinicopathological findings were retrospectively evaluated and compared between the CK-19-positive and CK-19-negative cHCC-CCA groups. RESULTS: One hundred seventy-four patients (mean age, males vs females: 56.6 ± 10.0 years vs 54.7 ± 14.2 years) were evaluated. The presence of mosaic architecture, targetoid appearance, cholangiectasis, hepatic capsule retraction, and corona enhancement was significantly higher in the CK-19-positive group (all p < 0.05), while nonrim arterial phase hyperenhancement (APHE) was more common in the CK-19-negative group (p = 0.04). The univariate analysis showed that hepatitis B virus infection, CEA > 5 ng/mL, tumor size, nonrim APHE, mosaic architecture, targetoid appearance, cholangiectasis, hepatic capsule retraction, and corona enhancement were significant risk factors for CK-19-positive cHCC-CCA (all p < 0.05). Unfortunately, the multivariate analysis revealed that only corona enhancement (OR = 2.359, p = 0.03) was an independent risk factor associated with CK-19-positive cHCC-CCA. CONCLUSION: Corona enhancement is significantly correlated with CK-19 positivity in patients with cHCC-CCA. Dove 2021-08-21 /pmc/articles/PMC8387586/ /pubmed/34458204 http://dx.doi.org/10.2147/JHC.S325686 Text en © 2021 Zhou et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zhou, Changwu
Ni, Xiaoyan
Lu, Xin
Wang, Yi
Qian, Xianling
Yang, Chun
Zeng, Mengsu
MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
title MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
title_full MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
title_fullStr MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
title_full_unstemmed MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
title_short MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma
title_sort mr features based on li-rads ver. 2018 correlated with cytokeratin 19 expression in combined hepatocellular carcinoma-cholangiocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8387586/
https://www.ncbi.nlm.nih.gov/pubmed/34458204
http://dx.doi.org/10.2147/JHC.S325686
work_keys_str_mv AT zhouchangwu mrfeaturesbasedonliradsver2018correlatedwithcytokeratin19expressionincombinedhepatocellularcarcinomacholangiocarcinoma
AT nixiaoyan mrfeaturesbasedonliradsver2018correlatedwithcytokeratin19expressionincombinedhepatocellularcarcinomacholangiocarcinoma
AT luxin mrfeaturesbasedonliradsver2018correlatedwithcytokeratin19expressionincombinedhepatocellularcarcinomacholangiocarcinoma
AT wangyi mrfeaturesbasedonliradsver2018correlatedwithcytokeratin19expressionincombinedhepatocellularcarcinomacholangiocarcinoma
AT qianxianling mrfeaturesbasedonliradsver2018correlatedwithcytokeratin19expressionincombinedhepatocellularcarcinomacholangiocarcinoma
AT yangchun mrfeaturesbasedonliradsver2018correlatedwithcytokeratin19expressionincombinedhepatocellularcarcinomacholangiocarcinoma
AT zengmengsu mrfeaturesbasedonliradsver2018correlatedwithcytokeratin19expressionincombinedhepatocellularcarcinomacholangiocarcinoma